Corsera Health Secures $80M for Cardiovascular Prevention
January 11, 2026, 3:45 am
Corsera Health secured an $80 million Series A. This capital fuels the company's mission to revolutionize cardiovascular health. It advances preventive RNAi medicines, targeting key drivers: LDL cholesterol and high blood pressure. These once-annual treatments aim for widespread access. An AI platform predicts disease risk. Initial clinical trials have begun. Proof-of-concept data is expected this year.
Corsera Health is redefining cardiovascular care. The Boston-based company announced a significant funding milestone. It raised an oversubscribed $80 million in Series A financing. This investment accelerates its vision. The company focuses on predicting and preventing heart disease. It aims to shift the paradigm of cardiovascular health.
Forbion and Population Health Partners co-led the funding round. Other investors also participated. Corsera Co-Founder and Co-CEO John Maraganore, Ph.D., was among them. Marco Boorsma, Ph.D., a General Partner at Forbion, joins Corsera Health’s board of directors. This new board appointment strengthens strategic guidance.
The capital infusion will fuel Corsera’s ambitious programs. A primary focus is its preventive RNAi medicine pipeline. This innovative approach targets the core causes of cardiovascular disease. It aims for a proactive stance. The goal is to stop heart conditions before they develop.
Cardiovascular disease remains a global health crisis. Traditional methods often treat symptoms. Corsera seeks to prevent the disease's onset entirely. Its RNAi medicines offer this promise. They are designed for long-term protection. This could transform patient outcomes.
The company's RNAi strategy is precise. It involves silencing specific genes. These genes are known drivers of heart disease. One target is low-density lipoprotein cholesterol (LDL-C). High LDL-C levels contribute to plaque buildup. This leads to atherosclerotic cardiovascular disease (ASCVD).
Corsera's lead candidate is COR-1004. This investigational siRNA targets PCSK9. PCSK9 is a protein linked to high LDL-C. Silencing PCSK9 can significantly lower cholesterol. COR-1004 is administered subcutaneously. Its design aims for once-annual dosing.
A Phase 1 clinical trial for COR-1004 has begun. Subjects are now receiving doses. The primary objective is to assess safety and tolerability. Secondary objectives are crucial. They include measuring PCSK9 knockdown. Researchers also track LDL-C lowering. Pharmacokinetics of COR-1004 are under evaluation. Initial proof-of-concept data is anticipated in 2026. This data will be a vital indicator of COR-1004's potential.
The RNAi program includes another critical component. COR-2003 targets angiotensinogen (AGT). AGT plays a key role in blood pressure regulation. High blood pressure is a major risk factor for heart disease. Reducing AGT expression can effectively lower blood pressure.
A Phase 1 trial for COR-2003 is planned. It is expected to commence in mid-2026. Like COR-1004, COR-2003 will be a subcutaneously administered siRNA. Its development underscores a comprehensive approach. Corsera addresses multiple facets of cardiovascular risk.
Beyond medicines, Corsera Health pioneers predictive technology. The company develops Klotho. Klotho is a proprietary AI-enabled precision health platform. This platform is cutting-edge. It uses artificial intelligence to assess individual risk.
Klotho's capabilities are profound. It predicts lifetime cardiovascular disease risk. It quantifies the potential benefits of intervention. Specifically, it analyzes the impact of lowering LDL-C and blood pressure. The platform shows how these reductions can extend cardiovascular healthspan. Klotho empowers clinicians. It allows for highly personalized preventive strategies.
The vision is clear: widespread access to preventive care. Corsera designs its medicines for population-scale reach. Ease of use is a priority. Strategic pricing will ensure broad availability. This is not just for niche markets. It is for everyone at risk.
Co-CEOs Clive Meanwell, M.D., and John Maraganore, Ph.D., lead Corsera Health. Their combined expertise drives the company's innovation. They champion a future free from cardiovascular disease. Their leadership guides the integration of advanced science. They merge RNAi therapeutics with predictive AI.
This funding marks a pivotal moment for Corsera Health. It provides the resources needed for clinical advancement. The company moves from concept to tangible solutions. Its approach offers a radical departure from current care models. It aims for true prevention.
The Boston biotech sector continues to thrive. Corsera Health emerges as a leader in this space. Its focus on preventive RNAi medicines is innovative. Its AI platform adds another layer of sophistication. This holistic approach holds immense promise. It could fundamentally change how society tackles heart disease.
Corsera Health is on a mission. It aims to deliver longer, healthier lives. It offers hope for millions worldwide. The company's scientific rigor is evident. Its commitment to population health is strong. Initial clinical data for COR-1004 in 2026 will be closely watched. The journey toward a world without cardiovascular disease has truly begun.
Corsera Health is redefining cardiovascular care. The Boston-based company announced a significant funding milestone. It raised an oversubscribed $80 million in Series A financing. This investment accelerates its vision. The company focuses on predicting and preventing heart disease. It aims to shift the paradigm of cardiovascular health.
Forbion and Population Health Partners co-led the funding round. Other investors also participated. Corsera Co-Founder and Co-CEO John Maraganore, Ph.D., was among them. Marco Boorsma, Ph.D., a General Partner at Forbion, joins Corsera Health’s board of directors. This new board appointment strengthens strategic guidance.
The capital infusion will fuel Corsera’s ambitious programs. A primary focus is its preventive RNAi medicine pipeline. This innovative approach targets the core causes of cardiovascular disease. It aims for a proactive stance. The goal is to stop heart conditions before they develop.
Cardiovascular disease remains a global health crisis. Traditional methods often treat symptoms. Corsera seeks to prevent the disease's onset entirely. Its RNAi medicines offer this promise. They are designed for long-term protection. This could transform patient outcomes.
The company's RNAi strategy is precise. It involves silencing specific genes. These genes are known drivers of heart disease. One target is low-density lipoprotein cholesterol (LDL-C). High LDL-C levels contribute to plaque buildup. This leads to atherosclerotic cardiovascular disease (ASCVD).
Corsera's lead candidate is COR-1004. This investigational siRNA targets PCSK9. PCSK9 is a protein linked to high LDL-C. Silencing PCSK9 can significantly lower cholesterol. COR-1004 is administered subcutaneously. Its design aims for once-annual dosing.
A Phase 1 clinical trial for COR-1004 has begun. Subjects are now receiving doses. The primary objective is to assess safety and tolerability. Secondary objectives are crucial. They include measuring PCSK9 knockdown. Researchers also track LDL-C lowering. Pharmacokinetics of COR-1004 are under evaluation. Initial proof-of-concept data is anticipated in 2026. This data will be a vital indicator of COR-1004's potential.
The RNAi program includes another critical component. COR-2003 targets angiotensinogen (AGT). AGT plays a key role in blood pressure regulation. High blood pressure is a major risk factor for heart disease. Reducing AGT expression can effectively lower blood pressure.
A Phase 1 trial for COR-2003 is planned. It is expected to commence in mid-2026. Like COR-1004, COR-2003 will be a subcutaneously administered siRNA. Its development underscores a comprehensive approach. Corsera addresses multiple facets of cardiovascular risk.
Beyond medicines, Corsera Health pioneers predictive technology. The company develops Klotho. Klotho is a proprietary AI-enabled precision health platform. This platform is cutting-edge. It uses artificial intelligence to assess individual risk.
Klotho's capabilities are profound. It predicts lifetime cardiovascular disease risk. It quantifies the potential benefits of intervention. Specifically, it analyzes the impact of lowering LDL-C and blood pressure. The platform shows how these reductions can extend cardiovascular healthspan. Klotho empowers clinicians. It allows for highly personalized preventive strategies.
The vision is clear: widespread access to preventive care. Corsera designs its medicines for population-scale reach. Ease of use is a priority. Strategic pricing will ensure broad availability. This is not just for niche markets. It is for everyone at risk.
Co-CEOs Clive Meanwell, M.D., and John Maraganore, Ph.D., lead Corsera Health. Their combined expertise drives the company's innovation. They champion a future free from cardiovascular disease. Their leadership guides the integration of advanced science. They merge RNAi therapeutics with predictive AI.
This funding marks a pivotal moment for Corsera Health. It provides the resources needed for clinical advancement. The company moves from concept to tangible solutions. Its approach offers a radical departure from current care models. It aims for true prevention.
The Boston biotech sector continues to thrive. Corsera Health emerges as a leader in this space. Its focus on preventive RNAi medicines is innovative. Its AI platform adds another layer of sophistication. This holistic approach holds immense promise. It could fundamentally change how society tackles heart disease.
Corsera Health is on a mission. It aims to deliver longer, healthier lives. It offers hope for millions worldwide. The company's scientific rigor is evident. Its commitment to population health is strong. Initial clinical data for COR-1004 in 2026 will be closely watched. The journey toward a world without cardiovascular disease has truly begun.